Abstral is a formulation of fentanyl citrate available as a sublingual tablet. It dissolves quickly and is absorbed through the sublingual mucosa to provide rapid analgesia. In the UK, Abstral is licensed for the treatment of breakthrough cancer pain (BTcP) in patients with otherwise stable, baseline persistent pain that is managed with conventional opioids.